Sub-cortico-frontal encephalopathy and choreic movements related to recombinant interferon-α 2b;Encéphalopathie sous-cortico-frontale et mouvements choréiques liés à l'interféron-α 2b recombinant

Revue Neurologique

Volumn 158, Issue 5 I, 2002, Pages 567-572

  Moulignier, A ^a   Allo, S ^a   Singer, B ^b   Monge Strauss, M F ^a   Zittoun, R ^c   Gout, O ^a  

^a FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

AGED; ARTICLE; BLOOD DISEASE; BRAIN BLOOD VESSEL; BRAIN DISEASE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHOREA; COGNITIVE DEFECT; CYTOKINE RELEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; NEUROENDOCRINE SYSTEM; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUROTRANSMISSION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATAXIA; BIOLOGICAL RESPONSE MODIFIERS; CENTRAL NERVOUS SYSTEM DISEASES; CHOREA; COGNITION DISORDERS; COMBINED MODALITY THERAPY; CONFUSION; FEMALE; FRONTAL LOBE; HUMANS; INTERFERON ALFA-2B; LEUKEMIA, MYELOID, CHRONIC; MEMORY DISORDERS; MULTIPLE MYELOMA; NEUROPSYCHOLOGICAL TESTS; PYRAMIDAL TRACTS;

EID: 17544401276     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma
2. Symptomatic myopathy associated with interferon therapy for chronic hepatitis C
3. Myasthenia gravis during interferon alpha therapy
4. Oculomotor nerve paralysis induced by alpha II-interferon
5. Bilateral neuralgic amyotrophy induced by interferon treatment
6. Central nervous system toxicity of interferons and other cytokines
7. Neurotoxicity of interferon-α in melanoma therapy. Results from a randomized controlled trial
8. Peripheral neuropathy during treatment with alpha-2 interferon
9. Infarctus cérébraux multiples associés à un livedo secondaires à un traitement anticancéreux par interleukine 2 et interféron alpha
10. The FAB: A Frontal Assessment Battery at bedside
11. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate. MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis
12. Unified Parkinson's disease rating scale
13. Mini Mental State a practical method for grading the cognitive state of patients for clinicians
14. Severe neuropathy associated with low-dose recombinant interferon-alpha
15. Rhabdomyolysis after treatment with interferon alpha
16. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alpha-2b and low dose cytarabine for chronic myelogenous leukemia: Analysis of cancer and leukemia group B 9013
17. Focal neurological signs and symptoms induced by interferon alpha in two patients with malignant melanoma
18. Symptomatic myopathy in hepatitis C infection without interferon therapy
19. Acute autonomic and sensory neuropathy after interferon alpha-2b therapy for chronic hepatitis C
20. Neuropathie périphérique au cours d'un traitement par interféron alpha
21. Neurotoxicity of interferon-alpha
22. Syndrome de persecution sous interféron: À propos d'un cas
23. Mononeuropathy multiplex in a patient receiving interferon alpha therapy for chronic hepatitis C
24. Development of myasthenia gravis during interferon-α treatment for anti-HCV positive chronic hepatitis
25. Interferon treatment of hepatitis C associated with symptoms of PTSD
26. Neurological function during long-term therapy with recombinant interferon alpha
27. Interferon related mental deterioration and behavioural changes in patients with renal cell carcinoma
28. Neurotoxicity of interferon-α
29. Interferon-related cortical blindness
30. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal spread
31. Persistent neurotoxicity of systematically administered interferon-alpha
32. Cognitive functioning in cancer patients: Effect of previous treatment
33. Neurological and psychiatric adverse effects of immunological therapy
34. Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C
35. A case of persistent manic depressive illness induced by interferon-alpha in the treatment of chronic hepatitis C
36. Acute axonal polyneuropathy during interferon α-2a therapy for chronic hepatitis type C
37. Factorial and discriminant validity of the Center for Epidemiological Studies Depression (CESD) scale
38. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
39. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-α therapy
40. Trijeminal sensory neuropathy induced by interferon-alpha therapy
41. Pulsions meurtrières chez deux malades atteints d'hépatite chronique C traités par interféron alpha
42. Central nervous toxicity of interferon
43. Multiple mononeuropathy during recombinant interferon-alpha-2a therapy for chronic hepatitis C
44. La polymyosite: Une complication rare du traitement par interféron alpha
45. A case of seizures 1 week after the cessation of interferon-alpha therapy
46. Seizures during alpha interferon therapy
47. Manic episodes in two patients treated with interferon alpha
48. Treatment of neurotoxic side effects of interferon-α with naltrexone
49. Drugs acting on the immune system
50. Treatment of carcinoma of the oesophagus with 5-fluorouracil and recombinant alfa 2a-interferon
51. Seizures in children during interferon alpha therapy
52. A case of chorea-like movement induced during interferon treatment of chronic hepatitis C